Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5708MR)

This product GTTS-WQ5708MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 1048
UniProt ID P07766; P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5708MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7028MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ2995MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ7377MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ13222MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ13203MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ9318MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ10224MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ6366MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW